• / Free eNewsletters & Magazine
  • / My Account
Home>Drug Companies

Drug Companies

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. UPDATE: Mylan offers price plan to help patients but its programs are still short on details

    UPDATE: Mylan offers price plan to help patients but its programs are still short on details

  2. Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg

    Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg

  3. UPDATE: Congress, Clinton join fight over rising cost of EpiPens as Shkreli defends

    UPDATE: Congress, Clinton join fight over rising cost of EpiPens as Shkreli defends

  4. Takeda Announces Bold, New Access to Medicines Strategy

    Takeda Announces Bold, New Access to Medicines Strategy

  5. AstraZeneca Sells Part of its Antibiotics Business to Pfizer -- Update

    AstraZeneca Sells Part of its Antibiotics Business to Pfizer -- Update

  6. S&P 500 closes at two-week low as health-care sector sinks

    S&P 500 closes at two-week low as health-care sector sinks

  7. Inotek Pharmaceuticals Announces the Completion of the Recruitment Phase of MATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma

    Inotek Pharmaceuticals Announces the Completion of the Recruitment Phase of MATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma

  8. Syros Pharmaceuticals to Present at BioCentury NewsMakers Conference

    Syros Pharmaceuticals to Present at BioCentury NewsMakers Conference

  9. SciQuest Gives Customers Full Control Over Chemical Inventory With Latest Enterprise Reagent Manager Upgrade

    SciQuest Gives Customers Full Control Over Chemical Inventory With Latest Enterprise Reagent Manager Upgrade

  10. World Diabetic Macular Edema Pipeline Review 2016 - Research and Markets

    World Diabetic Macular Edema Pipeline Review 2016 - Research and Markets

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.